Retension Pharmaceuticals, Inc. Form SCHEDULE 13D — Oct 14, 2026
Eric Keller, CEO, director, and co-founder of Retension Pharmaceuticals, filed a Schedule 13D disclosing beneficial ownership of 598,598 shares of common stock, representing 7.07% of the 8,331,599 shares outstanding immediately after the company's IPO. His stake results from founder share contributions, preferred stock purchases totaling roughly $463,000 across 2023-2025, stock option grants, and a $249,600 purchase of 20,800 IPO shares at $12.00 per share on October 13, 2026, after preferred shares converted to common at the IPO closing.
Key figures
- Shares Outstanding
- 8331599
- Ipostock option
- 255,174 shares at $11.63 exercise price
- Percent of class
- 7.07%
- Prior option 2024
- 500,000 shares at $0.23 exercise price (post-split adjusted)
- Prior option 2025
- 800,000 shares at $0.39 exercise price (post-split adjusted)
- Ipo purchase price
- $12.00 per share
- Ipo purchase total
- 249600
- Ipo purchase shares
- 20800
- Reverse split ratio
- 1:6.21
- Beneficial ownership shares
- 598598
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.